Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients

Todd Neale

September 12, 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

Todd Neale

May 19, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

L.A. McKeown

August 30, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Daily News

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

L.A. McKeown

October 10, 2023

News Daily News

Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data

Caitlin E. Cox

July 19, 2023

News Conference News ESC Heart Failure 2023

Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial

Shelley Wood

May 23, 2023

Presentation THT 2023

Will Gene Therapy With CRISPR Cure ATTR-CA?

Presenter: Ahmad Masri

March 21, 2023

Presentation THT 2023

Dichotomizing ATTR-CA Into Neurologic and Cardiac Phenotypes Is So 2010..What Works For One Works For the Other

Presenter: John Berk

March 21, 2023

Presentation THT 2023

Are We Ready to Start Systematic Screening for ATTR-CA? AS Early Diagnosis is Key

Presenter: Julie Rosenthal

March 21, 2023

Presentation THT 2023

Cardiovascular Hospitalization Rates in ATTR-CA: What Factors Make a Difference

Presenter: Margaret Cuomo

March 21, 2023

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

Todd Neale

October 20, 2021

Advertisement

Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

Acoramidis Approved in Europe for ATTR Cardiomyopathy

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data

Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial

Will Gene Therapy With CRISPR Cure ATTR-CA?

Dichotomizing ATTR-CA Into Neurologic and Cardiac Phenotypes Is So 2010..What Works For One Works For the Other

Are We Ready to Start Systematic Screening for ATTR-CA? AS Early Diagnosis is Key

Cardiovascular Hospitalization Rates in ATTR-CA: What Factors Make a Difference

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content